Skip to main content
. Author manuscript; available in PMC: 2012 May 3.
Published in final edited form as: Clin Immunol. 2001 Nov;101(2):237–247. doi: 10.1006/clim.2001.5109

Fig. 3.

Fig. 3

(a) CTLe activity in SCID1 PBMC against EIAV-infected homologous (closed circles) and heterologous (open circles) equine kidney (EK) cell targets. Effector:target cell ratio was 20:1. Error bars are standard error. (b) Frequency of EIAV-specific CTLe in SCID1 PBMC, as determined by limiting dilution analysis. Error bars indicate 95% confidence interval.